Recurrent UTIs in women - what's the evidence for non-antibiotic prophylaxis?

There is a growing and increasingly robust evidence base for non-antibiotic prophylaxis of recurrent UTIs (rUTIs) in women. Here's a summary of the key options and their evidence:

Vaginal Oestrogen (Postmenopausal Women)

This has the strongest evidence among non-antibiotic options for postmenopausal women. The AUA/CUA/SUFU 2025 guideline gives a moderate recommendation (Grade B) to recommend vaginal oestrogen therapy in perimenopausal and postmenopausal women with rUTIs. A meta-analysis of eight studies (~5,000 women) found vaginal oestrogen significantly reduced rUTIs compared to placebo (RR 0.42). An RCT comparing vaginal oestrogen to placebo showed significantly fewer women experienced a UTI within 6 months (50% vs 94%, p = 0.041), with the oestradiol ring appearing particularly effective (38% vs 91%). Importantly, oral oestrogen has not shown benefit.

Mechanism: oestrogen increases glycogen in vaginal mucosa, promoting Lactobacillus colonisation, lowering vaginal pH, and inhibiting uropathogen growth.

Cranberry Products

The AUA/CUA/SUFU 2025 guideline gives a moderate recommendation (Grade B) to offer cranberry for prophylaxis. A 2023 Cochrane review found cranberry products reduced rUTI risk by approximately 25% in certain groups including women. The EAU also recommends cranberry to prevent recurrent cystitis, citing a favourable benefit-harm profile. Proanthocyanidins (PACs) prevent E. coli adherence to uroepithelial cells.

Practical considerations: not all cranberry products are equivalent. Standardised formulations containing 36 mg of PACs are preferred; 200-300 mL of juice daily or 500 mg daily of cranberry fruit powder are commonly cited dosing regimens.

Methenamine Hippurate

The landmark ALTAR trial (UK, multicentre, open-label, non-inferiority RCT, n=240) demonstrated that methenamine hippurate 1g BD is non-inferior to daily low-dose prophylactic antibiotics for preventing rUTIs over 12 months. UTI incidence was 1.38 vs 0.89 episodes per person-year (absolute difference 0.49, within the non-inferiority margin of 1). The key advantage: antimicrobial resistance was proportionally higher in the antibiotic arm, and overall antibiotic use was lower with methenamine.

The AUA 2025 guideline gives a conditional recommendation (Grade C) to offer methenamine hippurate for prophylaxis. Dose: 1g orally twice daily. Works by converting to formaldehyde in acidic urine (pH <6), so checking urine pH and co-supplementing with vitamin C or cranberry may enhance effectiveness. Avoid in renal impairment, severe hepatic impairment, or with sulphonamides.

D-Mannose

Evidence has shifted. While earlier small trials (e.g. Kranjcec 2014) showed benefit vs placebo, a recent larger JAMA RCT found D-mannose may not be effective alone. The AUA 2025 guideline now specifically recommends informing patients that D-mannose alone may not be effective (Moderate Recommendation, Grade B). The EAU notes contradictory evidence on D-mannose efficacy.

Increased Water Intake

For women drinking <1.5L/day, an open-label RCT of 140 women showed that increasing intake by 1.5L/day resulted in a 50% reduction in UTI episodes (1.7 vs 3.2) and antibiotic courses (1.9 vs 3.6) over 12 months. A meta-analysis of seven studies (875 patients) reported a significant 64% risk reduction (RR 0.46, 95% CI 0.40-0.54). Low cost, no harms, but conditional recommendation (Grade C) in AUA 2025.

Immunomodulation

A systematic review and meta-analysis of 14 studies (2,822 patients) across five agent types (StroVac, OM-89, ExPEC4V, MV140, Solco-Urovac) showed patients treated with immunomodulation were ~50% more likely to remain cystitis-free at 6-12 months (pooled RR 1.52, 95% CI 1.05-2.20, NNT 6.45). The EAU supports this approach, though access varies by jurisdiction. OM-89 (Uro-Vaxom) has the most data. Availability in Australia is limited.

Probiotics

Evidence is not conclusive for rUTI prevention with Lactobacillus spp. probiotics. Some women choose to trial them, particularly after repeated antibiotic courses, but major guidelines do not make strong recommendations.